Search

HOLON: Compugen Ltd has issued the following news release: Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that [...]

FOSTER CITY: Gilead Sciences, Inc has issued the following news release: Gilead Sciences, Inc. (Nasdaq: GILD) today announced an agreement with Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer [...]

Conference call today, December 19, 2023, 8:30 AM ET to discuss the license agreement HOLON, Israel, Dec. 19, 2023 /PRNewswire/ -- http://www.cgen.com/(Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company [...]

- Gilead Will Have Exclusive Rights to Later Stage Development and Commercialization of Anti-IL18 Binding Protein Antibodies with Potential to Treat Various Tumor Types - - Gilead to Make $60 [...]

FOSTER CITY, Calif. & HOLON, Israel--(BUSINESS WIRE)--Dec 19, 2023-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced an agreement with https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.cgen.com%2F&esheet=53872742&newsitemid=20231218814564&lan=en-US&anchor=Compugen+Ltd.&index=1&md5=6f2a9acc188e71196da7eacea4864812 (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and [...]

CAMBRIDGE: Nona Biosciences has issued the following news release: Nona Biosciences, a global biotechnology company providing a total solution from 'Idea to IND' (I to ITM), ranging from target validation [...]

Nona Biosciences will receive a total of up to $53 Million in upfront and near-term payments, with the potential for milestones of up to $1.05 billion plus royalties. Pfizer partnership [...]

CAMBRIDGE: Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that the Company and Vertex Pharmaceuticals entered into a license agreement. Under terms of the agreement, Vertex [...]

DUBLIN: Research and Markets has issued the following news release: The 'Licensing Deals in Biotechnology 2019-2023' report has been added to ResearchAndMarkets.com's offering. The report on Licensing Deals in Biotechnology [...]

Vertex Pharmaceuticals to obtain a non-exclusive license for Cas9 for CASGEVY(TM) (exagamglogene autotemcel) Agreement extends Editas Medicine's cash runway into 2026 CAMBRIDGE, Mass., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Editas [...]

DUBLIN, Dec. 12, 2023 /PRNewswire/ -- The https://www.researchandmarkets.com/reports/5869883/licensing-deals-in-biotechnology?utm_source=CI&utm_medium=PressRelease&utm_code=mqg93q&utm_campaign=1918156+-+World+Biotechnology+Licensing+Deals+Analysis+Report+2023%3a+Gain+Access+to+Upfront%2c+Milestone%2c+and+Royalties+Data&utm_exec=chdo54prd report has been added toResearchAndMarkets.com's offering. The report on Licensing Deals in Biotechnology offers a comprehensive analysis of how and why companies [...]

SAN DIEGO: Skye Bioscience, Inc. (Skye), a pharmaceutical company developing drugs targeting the endocannabinoid system, and Tautomer Bioscience (Pty) Limited (Tautomer), a privately-owned biopharmaceutical company focused on addressing unmet medical [...]

GAITHERSBURG, Md. -- The following information was released by Novavax, Inc.: Novavaxá'sá partner, áSK bioscience,átoday announced that áNovavax's updated COVID-19 vaccine (NVX-CoV2601) has received Emergency Use Authorization áfromá the Ministry [...]

SOMERSET: Legend Biotech Corporation (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced that Legend Biotech Ireland Limited, a wholly owned subsidiary [...]

* The deal with Novartis seeks to advance Legend Biotech's autologous CAR-T cell therapy candidate, LB2102, and other potential CAR-T cell therapies targeting Delta-like ligand protein 3 (DLL3), using the [...]

Tokyo, Japan and Cambridge: Sosei Group Corporation has issued the following news release: Sosei Group Corporation ('Sosei Heptares' or 'the Company'; TSE: 4565) will receive a US$3.75 million milestone payment [...]

GenEdit, a developer of genetic medicines that leverage its NanoGalaxy platform for tissue-selective delivery, reported a multiyear collaboration and license agreement with Genentech, a member of the Roche Group. The [...]

GenEdit reported a multiyear collaboration and license agreement with Genentech, a member of the Roche Group. According to a media release, the companies will employ GenEdit's NanoGalaxy platform to discover [...]

Tokyo, Japan and Cambridge, UK, 31 October 2023 - Sosei Group Corporation ('Sosei Heptares' or 'the Company'; TSE: 4565) will receive a US$3.75 million milestone payment under the 2019 multi-target [...]

DUBLIN: ERS Genomics has issued the following news release: ERS Genomics, co-founded by Dr. Emmanuelle Charpentier, a recipient of the 2020 Nobel Prize in Chemistry for her pioneering work on [...]

SAN DIEGO: Hummingbird Bioscience ('Hummingbird Bio') a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, and Endeavor BioMedicines ('Endeavor'), a clinical-stage company targeting the drivers [...]

Endeavor obtains exclusive worldwide rights to Hummingbird Bioscience's anti-HER3 ADC to be developed for patients with HER3-expressing tumors Hummingbird Bioscience to receive upfront and milestone payments up to $430 million, [...]

(GlobeNewswire) - Yield10 Bioscience, Inc. (Nasdaq:YTEN) (Yield10 or the Company), an agricultural bioscience company, today announced that the Company has exercised its option to finalize an exclusive global, commercial license [...]

WOBURN, Mass., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) ('Yield10' or the 'Company'), an agricultural bioscience company, today announced that the Company has exercised its option to [...]

SAN DIEGO: Dare Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced the first shipment of XACIATOTM [pronounced zah-she-AH-toe] (clindamycin phosphate) vaginal gel, 2% in connection with [...]

SAN DIEGO, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Dare Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced the first shipment of XACIATOTM [pronounced zah-she-AH-toe] (clindamycin phosphate) [...]

SUZHOU, China, Oct. 12, 2023 /PRNewswire/ -- MediLink Therapeutics ('MediLink'), announced today that it has entered into a strategic research collaboration and worldwide license agreement with BioNTech SE (Nasdaq: BNTX, [...]

PISCATAWAY: KASHIV BIOSCIENCES LLC has issued the following news release: Kashiv Biosciences LLC ('Kashiv'), a fully integrated biopharmaceutical company, and Alvotech (NASDAQ: ALVO), a global biotech company specializing in the [...]

Helsinki: Alvotech S.A. has issued the following news release: Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Kashiv [...]

CLEVELAND & LEXINGTON, Ky. -- Athersys, Inc. (Nasdaq: ATHX), a cell therapy and regenerative medicine company developing MultiStem([R]) (invimestrocel) for critical care indications, and Multipotent Adult Progenitor Cell (MAPC([R])) technology [...]

REYKJAVIK, Iceland and PISCATAWAY, N.J., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide [...]

PISCATAWAY, N.J. & REYKJAVIK, Iceland -- Kashiv Biosciences LLC ('Kashiv'), a fully integrated biopharmaceutical company, and Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of [...]

SHANGHAI: Everest Medicines has issued the following news release: Everest Medicines (HKEX 1952.HK, 'Everest', or the 'Company'), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines [...]

The non-exclusive, multi-year license and supply agreement enables use of LentiVector with any Kyverna product Agreement supports Kyverna's scalability and reliability of CAR T cell manufacturing goals EMERYVILLE, Calif., Sept. [...]

SHANGHAI, Sept. 20, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, 'Everest', or the 'Company'), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced [...]

SUZHOU, China and HONG KONG, Sept. 14, 2023 /PRNewswire/ --Cure Genetics andFrametact Limited , a biotech company specializing in researching and developing treatments for neurological diseases, jointly announce the signing [...]

License allows AlgenScribe to expand its research and development activities using CRISPR/Cas9. DUBLIN and NICE, France, Sept. 5, 2023 /PRNewswire/ -- ERS Genomics Limited ('ERS') is pleased to announce a [...]

HOLON, Israel, Aug. 31, 2023 /PRNewswire/ -- http://www.cgen.com/(Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will present virtually [...]

Day One receives an exclusive license to develop and commercialize small molecule drug candidates for pediatric and adult cancers with high unmet need Collaboration augments Day One's portfolio of targeted [...]

DUBLIN: ERS Genomics Limited (ERS) announced a new license agreement with Santa Cruz Biotechnology Inc (SCBT). This is a non-exclusive licensing agreement granting SCBT access to the ERS CRISPR/Cas9 patent [...]

- Preclinical siRNA Targeting TMPRSS6 is a Potential Disease-Modifying Treatment for Polycythemia Vera - - Agreement Combines Agios' Scientific Expertise and Capabilities in Rare Hematologic Diseases with Alnylam's Industry-Leading siRNA [...]

Precision BioSciences, an advanced gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, [...]